Wockhardt shares rise 10% after Zaynich aids successful liver transplant trial
Wockhardt’s shares surged 8.6% after its antibiotic Zaynich successfully treated a US cancer patient, enabling a liver transplant and chemotherapy. The drug is nearing Phase III trials for global approval.
